# DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Source: https://onco.cc/trials/nct05768178/  
OnCo record `nct05768178` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of vemurafenib and cobimetinib in colorectal cancer, run by Cancer Research UK, now recruiting.

## Summary

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. is a phase 2/3, interventional study registered as NCT05768178 by Cancer Research UK, with a registry enrolment figure of 30 participants, started 2023-03-01 and due to reach its primary completion in 2029-10. Interventions recorded: Vemurafenib; Cobimetinib. Conditions listed: Haematological Malignancy; Melanoma; Thyroid Cancer, Papillary; Ovarian Neoplasms; Colorectal Neoplasms; Laryngeal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioma; Multiple Myeloma; Erdheim-Chester Disease; Thyroid Carcinoma, Anaplastic; Solid Tumour. Primary outcome: Objective Response (OR); Durable Clinical Benefit (DCB). Colorectal eligibility wording from the registry: "Patients with QTcF (Corrected QT interval by Fridericia) at screening of \>450 ms for males and \>470 ms for females measured on triplicate ECG (if 1/3 readings show \>450/470 ms then patient is ineligible)". Sites: United Kingdom. United Kingdom sites listed: 16. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: DETERMINE
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05768178
- Phase: 2/3
- Setting: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations.
- Sponsor: Cancer Research UK
- Enrolled: 30

## Notes

- UK sites (registry): Belfast City Hospital (Belfast); University Hospital Birmingham (Birmingham); Bristol Haematology and Oncology Centre (Bristol); Addenbrooke's Hospital (Cambridge); Velindre Cancer Centre (Cardiff); Western General Hospital (Edinburgh); The Beatson Hospital (Glasgow); Leicester Royal Infirmary (Leicester); University College London Hospital (London); Guy's Hospital (London); The Christie Hospital (Manchester); Clatterbridge Cancer Centre (Metropolitan Borough of Wirral) and 4 more.

## Sources

- ClinicalTrials.gov NCT05768178: https://clinicaltrials.gov/study/NCT05768178

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Cobimetinib](https://onco.cc/drugs/cobimetinib/), [Vemurafenib](https://onco.cc/drugs/vemurafenib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05768178.json